Sign up for our eNews and discover more about what we're up to, the difference we're making, and, most importantly, how you can help.
Researchers will test a new drug treatment that may help the brain remove toxins associated with the development of Alzheimer’s disease, after receiving a Dementia Australia Research Foundation grant.
The $375,000 Faye Williams Innovation Grant was awarded to a team led by Professor Michael Parker from St Vincent’s Institute of Medical Research to test the new drug treatment.
Professor Parker said the grant would enable them to move to the next stage of testing the new drug.
“If we can successfully enhance the brain’s ability to clear these toxins, we delay, and even potentially reverse, some of the symptoms of Alzheimer’s disease,” Professor Parker said.
“The brain naturally has cells that act as garbage collectors by removing the toxins that are associated with Alzheimer’s disease.
“We have some very promising preliminary results that indicate that the new drug we have developed can enhance this process without the negative consequences that have plagued drug trials."
The Dementia Australia Research Foundation acknowledges the generosity of Faye Williams who has supported these research grants.
Dementia is the second leading cause of death in Australia and Alzheimer’s disease is the most common form of dementia. Investment in research will help minimise its impact in the future and help find a cure.
For more information about Dementia Australia Research Foundation grants, or to donate to the Foundation please visit: https://www.dementia.org.au/research/grants
No results found.